Does Rallies show Form 4 insider transactions for VKTX?

Yes. Rallies tracks VKTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VKTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.

VKTX (Viking Therapeutics) Stock Analysis - Insider Trades

Viking Therapeutics (VKTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VKTX trades at $29.41 with a market cap of $3.33B and a P/E ratio of -9.16. VKTX moved +3.56% today. Year to date, VKTX is -8.40%; over the trailing twelve months it is +2.69%. Its 52-week range spans $18.92 to $81.73. Analyst consensus is strong buy with an average price target of $95.63. Rallies surfaces VKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VKTX stock inside the company?

Recent VKTX insider activity includes Aubuchon Neil William bought 4.47K, ZANTE GREG sold 31.96K, ZANTE GREG sold 13.90K, ZANTE GREG sold 10.30K, and ZANTE GREG sold 1.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VKTX Key Metrics

Key financial metrics for VKTX
Metric	Value
Price	$29.41
Market Cap	$3.33B
P/E Ratio	-9.16
EPS	$-3.19
Dividend Yield	0.00%
52-Week High	$81.73
52-Week Low	$18.92
Volume	1.41M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-359.64M
Gross Margin	0.00%

Recent VKTX Insider Trades

Aubuchon Neil William bought 4.47K (~$149.91K) on Mar 10, 2026.
ZANTE GREG sold 31.96K (~$1.03M) on Jan 5, 2026.
ZANTE GREG sold 13.90K (~$464.02K) on Jan 5, 2026.
ZANTE GREG sold 10.30K (~$352.63K) on Jan 5, 2026.
ZANTE GREG sold 1.50K (~$48.13K) on Jan 5, 2026.

Latest VKTX News

Viking Therapeutics to Present Phase 2 Weight Loss Data and Phase 3 Enrollment at ECO 2026 — May 5, 2026
Ends Q1 with $603 M Cash, Enrolls 5,500 in Phase 3 VK2735 Trials — Apr 29, 2026
Jefferies Reaffirms Buy as Viking Therapeutics Gains 16.5%; VK2735 Oral Study Slated — Mar 12, 2026
Viking Therapeutics Shares Drop 1.96%, Q1 EPS Forecast at -$1.01 — Mar 5, 2026
Viking Therapeutics Shares Surge Over 10% After Competitor’s Obesity Drug Miss — Feb 23, 2026

VKTX Analyst Consensus

10 analysts cover VKTX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.63.

Common questions about VKTX

Who is trading VKTX stock inside the company?: Recent VKTX insider activity includes Aubuchon Neil William bought 4.47K, ZANTE GREG sold 31.96K, ZANTE GREG sold 13.90K, ZANTE GREG sold 10.30K, and ZANTE GREG sold 1.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VKTX?: Yes. Rallies tracks VKTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VKTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.